NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals was added to the Russell 3000 and Russell 2000 after the markets closed on June 30, the company said today.
Alynlam said its inclusion in these indexes reflects an interest "in the potential of RNAi for therapeutic applications, and the promise of this technology," said John Maraganore, president and CEO of Alnylam Pharmaceuticals.
The Russell Indeces include only common stocks belonging to US corporations. The Russell 3000 measures the performance based on total market capitalization. Alnylam's market cap is currently $471 million.
Also listed on this index are: Applied Biosystems, Affymetrix, Agilent, Beckman Coulter, Becton Dickinson, Bio-Rad, Bruker BioSciences, Cepheid, DeCode, Fisher Scientific, General Electric, Illumina, Invitrogen, Luminex, Molecular Devices, PerkinElmer, Serologicals, Sigma-Aldrich, Solexa (which was added earlier this week), Thermo Electron, and Waters.